Stockscreener 앱 받기
102.67
2.44%
2.45
시장 영업 전:
102.55
-0.12
-0.12%
전일 마감가:
$100.22
열려 있는:
$101.13
하루 거래량:
583.51K
Relative Volume:
1.11
시가총액:
$7.97B
수익:
-
순이익/손실:
$-224.29M
주가수익비율:
-26.33
EPS:
-3.9
순현금흐름:
$-185.06M
1주 성능:
-1.78%
1개월 성능:
-2.21%
6개월 성능:
+28.87%
1년 성능:
+43.37%
1일 변동 폭
$99.18
$104.11
1주일 범위
$97.24
$105.83
52주 변동 폭
$55.53
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
명칭
Nuvalent Inc
전화
508-446-2272
주소
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
102.67 | 7.78B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-12 | 개시 | Canaccord Genuity | Buy |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-03-14 | 업그레이드 | UBS | Neutral → Buy |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-10-24 | 개시 | UBS | Neutral |
| 2024-08-29 | 개시 | Barclays | Overweight |
| 2024-04-17 | 개시 | Jefferies | Buy |
| 2024-04-01 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 재개 | Guggenheim | Buy |
| 2024-02-23 | 개시 | Robert W. Baird | Outperform |
| 2023-09-27 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-24 | 개시 | Guggenheim | Buy |
| 2023-01-18 | 개시 | Wedbush | Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
모두보기
Nuvalent Inc 주식(NUVL)의 최신 뉴스
NUVL: Regulatory filings and commercial launches for ALK and ROS1 NSCLC therapies are on track for 2024 - TradingView
HC Wainwright Brokers Reduce Earnings Estimates for Nuvalent - MarketBeat
NUVLForm S-8Securities to be offered to employees in employee benefit plans - ADVFN Ltd
TD Asset Management Inc Increases Position in Nuvalent, Inc. $NUVL - MarketBeat
NUVL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Nuvalent Insider Sold Shares Worth $566,788, According to a Recent SEC Filing - marketscreener.com
Nuvalent Executives Sell Shares Under Trading Plan - TradingView
Nuvalent (NUVL) CDO exercises options and sells 5,500 shares under 10b5-1 plan - Stock Titan
Nuvalent (NUVL) CLO sells 5,500 shares after option exercise - Stock Titan
Nuvalent, Inc. (NUVL) Stock Analysis: A Biotech With A Promising 40.78% Upside Potential - DirectorsTalk Interviews
UBS Adjusts Price Target on Nuvalent to $138 From $132, Maintains Buy Rating - marketscreener.com
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - AOL.com
Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect? - Finviz
Does Nuvalent (NUVL) Have a Chance to Surge by 37.26% According to Wall Street Analysts? - Bitget
Nuvalent (NASDAQ:NUVL) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
Vanguard Group Inc. Raises Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug - Investing.com Australia
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results - The Malaysian Reserve
Nuvalent, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug By Investing.com - Investing.com South Africa
Nuvalent, Inc. SEC 10-K Report - TradingView
Nuvalent (NUVL) targets 2026 launches with ROS1 and ALK lung cancer drugs - Stock Titan
(NUVL) Risk Channels and Responsive Allocation - Stock Traders Daily
Nuvalent (NUVL) details 2025 results and key FDA milestones - Stock Titan
BRIEF-Nuvalent Q4 EPS USD -1.58 - TradingView
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - The Motley Fool
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a 41.94% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Nuvalent (NUVL) Projected to Post Earnings on Thursday - MarketBeat
Trust linked to Nuvalent (NUVL) files Form 144 to sell 1,650 shares - Stock Titan
Bank Watch: Is Nuvalent Inc forming a bullish divergenceMarket Risk Analysis & Fast Gain Swing Alerts - baoquankhu1.vn
(NUVL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans - MarketBeat
NUVL: Global launches of innovative ROS1 and ALK inhibitors drive growth and pipeline expansion - TradingView
Nuvalent honors women pioneers on Women in Science Day - Traders Union
Candriam S.C.A. Purchases 28,462 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Assessing Nuvalent (NUVL) Valuation As DCF Signals Upside Versus Current Market Pricing - Yahoo Finance
US Stocks Recap: Is Nuvalent Inc forming a bullish divergenceJuly 2025 PostEarnings & Reliable Breakout Forecasts - baoquankhu1.vn
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 – Company Announcement - Financial Times
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Barchart.com
Liquidity Mapping Around (NUVL) Price Events - Stock Traders Daily
Nuvalent, Inc. (NUVL) Investor Outlook: Biotechnology Innovator with a 37.73% Potential Upside - DirectorsTalk Interviews
Nuvalent, Inc. (NUVL): Investor Outlook With A 33% Potential Upside - DirectorsTalk Interviews
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Final Week: Is Nuvalent Inc benefiting from innovation trendsBreakout Watch & Long-Term Growth Plans - baoquankhu1.vn
Why (NUVL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 14,300 Shares of Stock - MarketBeat
Deborah Ann Miller Sells 700 Shares of Nuvalent (NASDAQ:NUVL) Stock - MarketBeat
Nuvalent Inc (NUVL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nuvalent Inc 주식 (NUVL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Noci Darlene | Chief Development Officer |
Feb 26 '26 |
Sale |
103.03 |
5,500 |
566,682 |
58,117 |
| Miller Deborah Ann | Chief Legal Officer |
Feb 26 '26 |
Option Exercise |
6.89 |
5,500 |
37,895 |
65,134 |
| Miller Deborah Ann | Chief Legal Officer |
Feb 26 '26 |
Sale |
103.05 |
5,500 |
566,788 |
59,634 |
0.11%
6.00%
자본화:
|
볼륨(24시간):